Our training program in pulmonary disease provides comprehensive research training for individuals with a serious commitment to a career in lung biology and biomedical research, particularly as it interfaces with clinical pulmonary medicine. Our primary premise has long been that lung disease represents major health problems in the U.S. and that progress toward improved understanding of the pathobiology of these diseases are required to make progress toward treatment and prevention. The program has a long history (30m years), training numerous physicians and scientists who have subscribed to this mission, and have become leaders in academic pulmonary medicine. The program is under new leadership and strives to maintain the previous scientific and training success, while adapting the next generation of researchers to new basic and translational science and technology. Recent changes have included expanded resources (recruitment of 24 new faculty members, and doubling the laboratory space). This has allowed us to broaden the scope of research questions related to lung biology, and attack the problems at the most basic and translational levels incorporating new cores in the Lung Biology ad Clinical Center Center and Harvard Medical Center. We have also enhanced our didactic program and further solidified program organization for oversight and mentoring of trainees. We identify trainees with a demonstrated interest in a research career. We also identify an environment where these individuals can pursue a problem of interest and in which creative and solid thinking combined with state-of-the-art technology is being used to pursue the problem, and provide them with the tools and mind-set to attack other problems in the future. Finally, we provide a prolonged period of support so that trainees are prepared to ultimately become a productive independent investigator, and the next leaders in pulmonary academics. Of the 38 trainees who have completed the program, 35 trainees in the last 10 years (92%) remain in academic medicine and research, 2 trainees are performing clinical research in industry, and only one trainee in the past decade is now in private practice. These trainees obtained 36 grant awards consisting of 20 NIH mentorship awards (K-and F Awards), 5 independent R-awards, 1 Project Leader on PPG, 2 Clinical Research Network grants, 3 Parker B. Francis awards, and 6 foundation awards (ATS/ALA, CF foundation), and have published 191 papers with their training grant mentors. As the Program Director of this training program, he will continue to work with the utmost enthusiasm and energy to ensure that the trainees of our training program will continue to excel and contribute significantly to the academic pulmonary community.

Public Health Relevance

Training program in pulmonary disease provides comprehensive research training for individuals with a serious commitment to a career in biomedical research focused on lung disease. Our primary goal is to train the next generation of physician scientist and scientist to become independent researchers in academic medicine to better understand the pathogenesis of lung disease and identify new therapeutic modalities in lung disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-M (O1))
Program Officer
Tigno, Xenia
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
González, Germán; Ash, Samuel Y; Vegas-Sánchez-Ferrero, Gonzalo et al. (2018) Disease Staging and Prognosis in Smokers Using Deep Learning in Chest Computed Tomography. Am J Respir Crit Care Med 197:193-203
Miller, Ezra R; Putman, Rachel K; Vivero, Marina et al. (2018) Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. Am J Respir Crit Care Med 197:955-958
Baron, Rebecca M; Kwon, Min-Young; Castano, Ana P et al. (2018) Frontline Science: Targeted expression of a dominant-negative high mobility group A1 transgene improves outcome in sepsis. J Leukoc Biol 104:677-689
Samokhin, Andriy O; Stephens, Thomas; Wertheim, Bradley M et al. (2018) NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Sci Transl Med 10:
Oldham, William M; Oliveira, Rudolf K F; Wang, Rui-Sheng et al. (2018) Network Analysis to Risk Stratify Patients With Exercise Intolerance. Circ Res 122:864-876
Sanders, Karin J C; Ash, Samuel Y; Washko, George R et al. (2018) Imaging approaches to understand disease complexity: chronic obstructive pulmonary disease as a clinical model. J Appl Physiol (1985) 124:512-520
Sham, Ho Pan; Walker, Katherine H; Abdulnour, Raja-Elie E et al. (2018) 15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-?B Regulators in Bacterial Pneumonia. J Immunol 200:2757-2766
Ash, Samuel Y; Harmouche, Rola; Putman, Rachel K et al. (2018) Association between acute respiratory disease events and the MUC5B promoter polymorphism in smokers. Thorax 73:1071-1074
Axelsson, Gisli Thor; Putman, Rachel K; Araki, Tetsuro et al. (2018) Interstitial lung abnormalities and self-reported health and functional status. Thorax 73:884-886
Maron, Bradley A; Wertheim, Bradley M; Gladwin, Mark T (2018) Under Pressure to Clarify Pulmonary Hypertension Clinical Risk. Am J Respir Crit Care Med 197:423-426

Showing the most recent 10 out of 190 publications